Alvaiz — CareFirst (Caremark)
Thrombocytopenia associated with chronic hepatitis C
Initial criteria
- Member is prescribed the requested drug for the initiation and maintenance of interferon-based therapy for treatment of thrombocytopenia associated with chronic hepatitis C
Reauthorization criteria
- Authorization of 6 months may be granted to members continuing interferon-based therapy
Approval duration
initial 12 months; continuation 6 months